Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8237)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Apr 28, 2015 (publication date) through May 8, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Seto WK. Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. World J Hepatol 2015; 7(6): 825-830 [PMID: 25937860 DOI: 10.4254/wjh.v7.i6.825] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v7/i6/825.htm |
| Number | Citing Articles |
| 1 |
C. Cerva, G. Maffongelli, V. Svicher, R. Salpini, L. Colagrossi, A. Battisti, B. Mariotti, R. Cerretti, L. Cudillo, L. Sarmati. Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal. BMC Infectious Diseases 2017; 17(1) doi: 10.1186/s12879-017-2672-6
|
| 2 |
Hae Lim Lee, Jeong Won Jang, Ji Won Han, Sung Won Lee, Si Hyun Bae, Jong Young Choi, Nam Ik Han, Seung Kew Yoon, Hee-Je Kim, Seok Lee, Seok-Goo Cho, Chang-Ki Min, Dong-Wook Kim, Jong Wook Lee. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B. Digestive Diseases and Sciences 2019; 64(10): 2992 doi: 10.1007/s10620-019-05614-6
|
| 3 |
Lorraine Jennings, Oonagh Molloy, Catherine Quinlan, Genevieve Kelly, Marina O'Kane. Treatment of pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) with weight‐based anakinra dosing in a Hepatitis B carrier. International Journal of Dermatology 2017; 56(6) doi: 10.1111/ijd.13528
|
| 4 |
Olga Timofeeva, James Brown. Immunological considerations—HLA matching and management of high immunological risk recipients. Indian Journal of Thoracic and Cardiovascular Surgery 2022; 38(S2): 248 doi: 10.1007/s12055-021-01201-5
|
| 5 |
Forough Golsaz-Shirazi, Fazel Shokri. Hepatitis B immunopathogenesis and immunotherapy. Immunotherapy 2016; 8(4): 461 doi: 10.2217/imt.16.3
|
| 6 |
Alessandro Loglio, Mauro Viganò, Glenda Grossi, Sara Labanca, Maria Goldaniga, Alessandra Pompa, Lucia Farina, Mariagrazia Rumi, Paolo Corradini, Floriana Facchetti, Giovanna Lunghi, Luca Baldini, Pietro Lampertico. Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma. Digestive and Liver Disease 2019; 51(3): 419 doi: 10.1016/j.dld.2018.08.024
|
| 7 |
Yi-Chia Su, Pei-Chin Lin, Hsien-Chung Yu, Chih-Chien Wu. Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis. European Journal of Clinical Pharmacology 2018; 74(9): 1111 doi: 10.1007/s00228-018-2487-4
|
| 8 |
Tomasz I. Michalak. Diverse Virus and Host-Dependent Mechanisms Influence the Systemic and Intrahepatic Immune Responses in the Woodchuck Model of Hepatitis B. Frontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.00853
|
| 9 |
Martin Feuchtenberger, Arne Schäfer, Axel Philipp Nigg, Michael Rupert Kraus. Hepatitis B Serology in Patients with Rheumatic Diseases. The Open Rheumatology Journal 2016; 10(1): 39 doi: 10.2174/1874312901610010039
|
| 10 |
Pranatharthi H. Chandrasekar, Miriam T. Levine. Occult Hepatitis B Virus Reactivation in a Seronegative Stem Cell Transplant Recipient. Infectious Diseases in Clinical Practice 2017; 25(2): 97 doi: 10.1097/IPC.0000000000000472
|
| 11 |
R. Pereira, I. Raposo, F. Nery, T. Torres. Risk of hepatitis B virus reactivation in patients treated with anti-TNFα agents for immune-mediated inflammatory diseases. Actas Dermo-Sifiliográficas (English Edition) 2018; 109(3): 285 doi: 10.1016/j.adengl.2017.07.018
|
| 12 |
Anca Raducan, Stefana Bucur, Constantin Caruntu, Traian Constantin, Iuliana Nita, Nicuta Manolache, Maria-Magdalena Constantin. Therapeutic management with biological anti-TNF-α agent in severe psoriasis associated with chronic hepatitis B: A case report. Experimental and Therapeutic Medicine 2019; doi: 10.3892/etm.2019.7567
|
| 13 |
Shih-Yu Yang, Tsung-Hui Hu, Yeh-Pin Chou, Yuan-Hung Kuo, Ming-Chao Tsai, Kuo-Chin Chang, Yi-Hao Yen, Po-Lin Tseng. Long-term comparisons of the durability of 6 months versus 12 months antiviral therapy for hepatitis B after chemotherapy cessation. Journal of Infection and Public Health 2023; 16(11): 1852 doi: 10.1016/j.jiph.2023.08.006
|
| 14 |
Ka-Shing Cheung, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen. Prevention and management of hepatitis B virus reactivation in cancer patients. Hepatology International 2016; 10(3): 407 doi: 10.1007/s12072-015-9692-3
|
| 15 |
Hae Lim Lee, Si Hyun Bae, Bohyun Jang, Seawon Hwang, Hyun Yang, Hee Chul Nam, Pil Soo Sung, Sung Won Lee, Jeong Won Jang, Jong Young Choi, Nam Ik Han, Byung Joo Song, Jong Wook Lee, Seung Kew Yoon. Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated with Systemic Chemotherapy or Immunosuppressive Therapy. Gut and Liver 2017; 11(6): 870 doi: 10.5009/gnl16434
|
| 16 |
R. Pereira, I. Raposo, F. Nery, T. Torres. Risk of hepatitis B virus reactivation in patients treated with anti-TNFα agents for immune-mediated inflammatory diseases. Actas Dermo-Sifiliográficas 2018; 109(3): 285 doi: 10.1016/j.ad.2017.07.011
|
| 17 |
Xueyuan Nian, Zhihui Xu, Yan Liu, Jianhong Chen, Xiaodong Li, Dongping Xu. Association between hepatitis B virus basal core promoter/precore region mutations and the risk of hepatitis B-related acute-on-chronic liver failure in the Chinese population: an updated meta-analysis. Hepatology International 2016; 10(4): 606 doi: 10.1007/s12072-016-9716-7
|
| 18 |
Rex Wan-Hin Hui, Lung Yi Mak, Wai-Kay Seto, Man-Fung Yuen. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials. Expert Opinion on Emerging Drugs 2022; 27(2): 127 doi: 10.1080/14728214.2022.2074977
|
| 19 |
Maria Guarino, Marco Picardi, Anna Vitiello, Novella Pugliese, Matilde Rea, Valentina Cossiga, Fabrizio Pane, Nicola Caporaso, Filomena Morisco. Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma. Annals of Hepatology 2017; 16(2): 198 doi: 10.5604/16652681.1231579
|